{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:52Z","timestamp":1793298952893,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T00:00:00Z","timestamp":1521849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"German Ministry of Health"},{"name":"German Federal Institute for Drugs and Medical Devices"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00392-018-1234-2","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T23:24:40Z","timestamp":1521847480000},"page":"679-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study"],"prefix":"10.1007","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-4247","authenticated-orcid":false,"given":"Maria","family":"Hoeltzenbein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Tissen-Diabat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Katrin","family":"Fietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Weber-Schoendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,24]]},"reference":[{"issue":"7","key":"1234_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00392-017-1095-0","volume":"106","author":"S Kulenthiran","year":"2017","unstructured":"Kulenthiran S, Ewen S, Bohm M, Mahfoud F (2017) Hypertension up to date: SPRINT to SPYRAL. Clin Res Cardiol 106(7):475\u2013484. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1095-0","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"1234_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00392-015-0939-8","volume":"105","author":"MN Hirt","year":"2016","unstructured":"Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T (2016) General practitioners\u2019 adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol 105(5):441\u2013450. \n                    https:\/\/doi.org\/10.1007\/s00392-015-0939-8","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"1234_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00392-017-1170-6","volume":"107","author":"C Tschope","year":"2018","unstructured":"Tschope C, Birner C, Bohm M, Bruder O, Frantz S, Luchner A, Maier L, Stork S, Kherad B, Laufs U (2018) Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the \u201cHeart Failure Working Group\u201d of the German Society of Cardiology (DKG). Clin Res Cardiol 107(1):1\u201319. \n                    https:\/\/doi.org\/10.1007\/s00392-017-1170-6","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"1234_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force M (2013) 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31(7):1281\u20131357. \n                    https:\/\/doi.org\/10.1097\/01.hjh.0000431740.32696.cc","journal-title":"J Hypertens"},{"issue":"4","key":"1234_CR5","doi-asserted-by":"publisher","first-page":"e36171","DOI":"10.1371\/journal.pone.0036171","volume":"7","author":"BT Bateman","year":"2012","unstructured":"Bateman BT, Shaw KM, Kuklina EV, Callaghan WM, Seely EW, Hernandez-Diaz S (2012) Hypertension in women of reproductive age in the United States: NHANES 1999\u20132008. PLoS One 7(4):e36171. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0036171","journal-title":"PLoS One"},{"issue":"3","key":"1234_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2125.2012.04388.x","volume":"75","author":"M Oppermann","year":"2013","unstructured":"Oppermann M, Padberg S, Kayser A, Weber-Schoendorfer C, Schaefer C (2013) Angiotensin-II receptor 1 antagonist fetopathy\u2014risk assessment, critical time period and vena cava thrombosis as a possible new feature. Br J Clin Pharmacol 75(3):822\u2013830. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04388.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1234_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HJH.0000000000000069","volume":"32","author":"KA Al Khaja","year":"2014","unstructured":"Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH (2014) Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens 32(3):454\u2013463. \n                    https:\/\/doi.org\/10.1097\/HJH.0000000000000069","journal-title":"J Hypertens"},{"issue":"2","key":"1234_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","volume":"60","author":"M Bullo","year":"2012","unstructured":"Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD (2012) Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60(2):444\u2013450. \n                    https:\/\/doi.org\/10.1161\/hypertensionaha.112.196352","journal-title":"Hypertension"},{"issue":"23","key":"1234_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa055202","volume":"354","author":"WO Cooper","year":"2006","unstructured":"Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354(23):2443\u20132451. \n                    https:\/\/doi.org\/10.1056\/NEJMoa055202","journal-title":"N Engl J Med"},{"issue":"11","key":"1234_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1097\/HJH.0000000000001456","volume":"35","author":"CA Fitton","year":"2017","unstructured":"Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, McLay JS (2017) In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens 35(11):2123\u20132137. \n                    https:\/\/doi.org\/10.1097\/HJH.0000000000001456","journal-title":"J Hypertens"},{"issue":"8","key":"1234_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/bdra.23027","volume":"94","author":"JE Polifka","year":"2012","unstructured":"Polifka JE (2012) Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Res Part A Clin Mol Teratol 94 (8):576\u2013598. \n                    https:\/\/doi.org\/10.1002\/bdra.23027","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"issue":"1","key":"1234_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/AOG.0000000000001775","volume":"129","author":"BT Bateman","year":"2017","unstructured":"Bateman BT, Patorno E, Desai RJ, Seely EW, Mogun H, Dejene SZ, Fischer MA, Friedman AM, Hernandez-Diaz S, Huybrechts KF (2017) Angiotensin-converting enzyme inhibitors and the risk of congenital malformations. Obstet Gynecol 129(1):174\u2013184. \n                    https:\/\/doi.org\/10.1097\/aog.0000000000001775","journal-title":"Obstet Gynecol"},{"key":"1234_CR13","doi-asserted-by":"publisher","first-page":"658310","DOI":"10.1155\/2012\/658310","volume":"2012","author":"ME Moretti","year":"2012","unstructured":"Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, Koren G (2012) The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstetr Gynecol Int 2012:658310. \n                    https:\/\/doi.org\/10.1155\/2012\/658310","journal-title":"Obstetr Gynecol Int"},{"issue":"4","key":"1234_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.reprotox.2011.02.008","volume":"31","author":"O Diav-Citrin","year":"2011","unstructured":"Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A (2011) Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 31(4):540\u2013545. \n                    https:\/\/doi.org\/10.1016\/j.reprotox.2011.02.008","journal-title":"Reprod Toxicol"},{"issue":"2","key":"1234_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/HJH.0b013e328341885d","volume":"29","author":"VJ Karthikeyan","year":"2011","unstructured":"Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG (2011) Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. J Hypertens 29(2):396\u2013399. \n                    https:\/\/doi.org\/10.1097\/HJH.0b013e328341885d","journal-title":"J Hypertens"},{"issue":"5","key":"1234_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00125-014-3188-x","volume":"57","author":"G Lewis","year":"2014","unstructured":"Lewis G, Maxwell AP (2014) Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Diabetologia 57(5):1082\u20131083. \n                    https:\/\/doi.org\/10.1007\/s00125-014-3188-x","journal-title":"Diabetologia"},{"issue":"1","key":"1234_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","volume":"26","author":"C Schaefer","year":"2008","unstructured":"Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C (2008) Using observational cohort data for studying drug effects on pregnancy outcome\u2014methodological considerations. Reprod Toxicol 26(1):36\u201341. \n                    https:\/\/doi.org\/10.1016\/j.reprotox.2008.05.064","journal-title":"Reprod Toxicol"},{"issue":"8","key":"1234_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/bdra.10081","volume":"67","author":"C Schaefer","year":"2003","unstructured":"Schaefer C (2003) Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A Clin Mol Teratol 67(8):591\u2013594. \n                    https:\/\/doi.org\/10.1002\/bdra.10081","journal-title":"Birth Defects Res Part A Clin Mol Teratol"},{"key":"1234_CR19","unstructured":"EUROCAT (2017) European surveillance of congenital anomalies: Malformation Coding Guides. \n                    http:\/\/www.eurocat-network.eu\/aboutus\/datacollection\/guidelinesforregistration\/malformationcodingguides\n                    \n                  . Accessed 24 Nov 2017"},{"issue":"1","key":"1234_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.reprotox.2008.06.006","volume":"26","author":"R Meister","year":"2008","unstructured":"Meister R, Schaefer C (2008) Statistical methods for estimating the probability of spontaneous abortion in observational studies\u2014analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 26(1):31\u201335. \n                    https:\/\/doi.org\/10.1016\/j.reprotox.2008.06.006","journal-title":"Reprod Toxicol"},{"issue":"1","key":"1234_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1055\/s-0029-1241833","volume":"214","author":"M Voigt","year":"2010","unstructured":"Voigt M, Rochow N, Hesse V, Olbertz D, Schneider KT, Jorch G (2010) Kurzmitteilung zu den Perzentilwerten f\u00fcr die K\u00f6rperma\u00dfe der Neugeborenen. Z Geburtshilfe Neonatol 214(1):24\u201329. \n                    https:\/\/doi.org\/10.1055\/s-0029-1241833","journal-title":"Z Geburtshilfe Neonatol"},{"issue":"28","key":"1234_CR22","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679. \n                    https:\/\/doi.org\/10.1002\/sim.6607","journal-title":"Stat Med"},{"issue":"1","key":"1234_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/HYPERTENSIONAHA.117.09110","volume":"70","author":"M Hoeltzenbein","year":"2017","unstructured":"Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, Padberg S, Weber-Schoendorfer C, Meister R, Schaefer C (2017) Pregnancy outcome after first trimester use of methyldopa: a prospective cohort study. Hypertension 70(1):201\u2013208. \n                    https:\/\/doi.org\/10.1161\/hypertensionaha.117.09110","journal-title":"Hypertension"},{"key":"1234_CR24","doi-asserted-by":"publisher","first-page":"337.e331-314","DOI":"10.1016\/j.ajog.2014.09.031","volume":"212","author":"BT Bateman","year":"2015","unstructured":"Bateman BT, Huybrechts KF, Fischer MA, Seely EW, Ecker JL, Oberg AS, Franklin JM, Mogun H, Hernandez-Diaz S (2015) Chronic hypertension in pregnancy and the risk of congenital malformations: a cohort study. Am J Obstet Gynecol 212:337.e331-314. \n                    https:\/\/doi.org\/10.1016\/j.ajog.2014.09.031","journal-title":"Am J Obstet Gynecol"},{"key":"1234_CR25","unstructured":"EUROCAT (2017) European surveillance of congenital, anomalies: prevalence Tables. \n                    http:\/\/www.eurocat-network.eu\/accessprevalencedata\/prevalencetable\n                    \n                  . Accessed 27 Sept 2017"},{"issue":"7","key":"1234_CR26","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s00246-015-1182-9","volume":"36","author":"A Ramakrishnan","year":"2015","unstructured":"Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ (2015) Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Pediatr Cardiol 36(7):1442\u20131451. \n                    https:\/\/doi.org\/10.1007\/s00246-015-1182-9","journal-title":"Pediatr Cardiol"},{"issue":"5","key":"1234_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/HYPERTENSIONAHA.116.08773","volume":"69","author":"SC Fisher","year":"2017","unstructured":"Fisher SC, Van Zutphen AR, Werler MM, Lin AE, Romitti PA, Druschel CM, Browne ML, The National Birth Defects Prevention S (2017) Maternal antihypertensive medication use and congenital heart defects: updated results from the national birth defects prevention study. Hypertension 69 (5):798\u2013805. \n                    https:\/\/doi.org\/10.1161\/hypertensionaha.116.08773","journal-title":"Hypertension"},{"issue":"11","key":"1234_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/BF03345344","volume":"28","author":"E Boix","year":"2005","unstructured":"Boix E, Zapater P, Pico A, Moreno O (2005) Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 28(11):1029\u20131031","journal-title":"J Endocrinol Invest"},{"key":"1234_CR29","doi-asserted-by":"publisher","first-page":"d5931","DOI":"10.1136\/bmj.d5931","volume":"343","author":"DK Li","year":"2011","unstructured":"Li DK, Yang C, Andrade S, Tavares V, Ferber JR (2011) Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 343:d5931. \n                    https:\/\/doi.org\/10.1136\/bmj.d5931\n                    \n                   \u00a0","journal-title":"BMJ"},{"issue":"6","key":"1234_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/pds.3613","volume":"23","author":"RA Charlton","year":"2014","unstructured":"Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsoyr K, Andersen AM, Hansen AV, Gini R, Bos JH, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-van den Berg LT, de Vries CS (2014) Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf 23(6):586\u2013594. \n                    https:\/\/doi.org\/10.1002\/pds.3613","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1234_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00392-015-0893-5","volume":"105","author":"M Hoeltzenbein","year":"2016","unstructured":"Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R (2016) Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol 105(2):117\u2013126. \n                    https:\/\/doi.org\/10.1007\/s00392-015-0893-5","journal-title":"Clin Res Cardiol"},{"key":"1234_CR32","doi-asserted-by":"publisher","first-page":"g2301","DOI":"10.1136\/bmj.g2301","volume":"348","author":"K Bramham","year":"2014","unstructured":"Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC (2014) Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ 348:g2301. \n                    https:\/\/doi.org\/10.1136\/bmj.g2301","journal-title":"BMJ"},{"issue":"11","key":"1234_CR33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCULATIONAHA.113.003904","volume":"129","author":"EW Seely","year":"2014","unstructured":"Seely EW, Ecker J (2014) Chronic hypertension in pregnancy. Circulation 129(11):1254\u20131261. \n                    https:\/\/doi.org\/10.1161\/circulationaha.113.003904","journal-title":"Circulation"},{"issue":"4","key":"1234_CR34","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.107.107565","volume":"51","author":"LC Chappell","year":"2008","unstructured":"Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH (2008) Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension 51(4):1002\u20131009. \n                    https:\/\/doi.org\/10.1161\/hypertensionaha.107.107565","journal-title":"Hypertension"},{"key":"1234_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.reprotox.2016.11.019","volume":"67","author":"E Beck","year":"2017","unstructured":"Beck E, Lechner A, Schaefer C (2017) Who seeks teratology information service\u2019s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol 67:79\u201384. \n                    https:\/\/doi.org\/10.1016\/j.reprotox.2016.11.019","journal-title":"Reprod Toxicol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-018-1234-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1234-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T20:47:16Z","timestamp":1553374036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-018-1234-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,24]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1007\/s00392-018-1234-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,24]]},"assertion":[{"value":"3 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}